Eli Lilly
15 articles
Industry NewsEli Lilly / Calytrix BioBioPharma Dive
Lilly's 15th Buyout of 2026: $1.5B for Calytrix's CALR Antibody
- Lilly will pay up to $1.5B for Calytrix Bio, with an undisclosed upfront and milestones tied to clinical and regulatory goals.
- Calytrix is developing a biparatopic antibody against a cell-surface protein in CALR-mutant disease, aimed at myelofibrosis and essential thrombocythemia.
- It is Lilly's 15th announced acquisition this year, over $30B in total, mostly of private startups.
Mutant-CALR targeting is the prize in myeloproliferative neoplasms: JAK inhibitors like Jakafi manage symptoms but don't go after the clone. Lilly is again buying early and cheaply, so the price is an option on unproven biology rather than on data. The undisclosed stage and upfront make it hard to judge; the key test is whether the antibody can spare normal cells while clearing mutant ones.
Industry NewsNovo Nordisk / Eli LillyBioSpace
FDA orders class-wide GLP-1 label update for potential risk of rare eye disease
- FDA is requiring all approved GLP-1 receptor agonists to add a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) to Warnings and Precautions; indications are unchanged.
- Twelve products are affected, including Wegovy, Ozempic, Zepbound and Mounjaro.
- A trial meta-analysis found 6.4 NAION events per 100,000 patient-years with GLP-1s versus 3.8 for comparators; FDA found no mechanism in animal data.
A Warnings-section addition rather than a boxed warning keeps the commercial hit modest, and the absolute difference is small. Still, class-wide wording denies Novo and Lilly any differentiation on eye safety. What's missing is mechanism and per-drug data; watch for ophthalmology-driven prescribing caution in high-risk patients.
Industry NewsEli LillySTAT News
Lilly's Oral GLP-1 Foundayo Cuts Sleep Apnea Events in a One-Year Study
- In a one-year trial in patients not using PAP therapy, Foundayo cut the apnea-hypopnea index by 17.8 events per hour versus 4.5 on placebo.
- About 28% of treated patients reached remission or mild disease, against 13% on placebo.
- Data were shown at the AHA meeting and published in JAMA; STAT notes the pill does not look as effective as injectable Zepbound.
Zepbound already holds the sleep apnea label, so the pill's role is breadth: a convenient option for the many apnea patients who also carry obesity, and a way to extend the franchise without needles or cold chain. Expect payers to ask whether a weaker oral effect justifies a new indication, and for Lilly to pitch it as a step-down or maintenance choice.
Industry NewsEli Lilly / Hims & HersBioPharma Dive
Lilly Lets Hims & Hers Prescribe Zepbound and Foundayo at Self-Pay Prices
- Lilly will offer Zepbound and its oral Foundayo through the Hims & Hers telehealth platform at the same self-pay prices available elsewhere, starting at $299 and $149 a month respectively.
- Hims previously sold cheaper compounded GLP-1s and changed course in March after a legal challenge from Novo, which struck a similar deal with it.
Both big GLP-1 makers now use Hims as a cash-pay channel, which turns a former adversary into distribution and removes the compounded-versus-branded argument from the telehealth funnel. For Lilly the signal is price discipline: self-pay tiers are set low enough that volume, not margin per script, is the bet. Watch whether Hims keeps compounded options for 'clinical necessity'.
Industry NewsEli LillyEndpoints News
Lilly Beats Q3 Revenue Estimates by About $2 Billion and Lifts Full-Year Guidance
- Lilly reported third-quarter revenue of $24.4 billion, up 39%, roughly $2 billion above Wall Street estimates, led by Mounjaro and Zepbound.
- Full-year revenue guidance rose by about $5.5 billion at the midpoint, to $91 to $92 billion.
- The quarter included about $900 million of non-recurring help, mainly $410 million of Jardiance milestones and favorable rebate adjustments.
Even stripped of the one-offs, the beat is large, and it widens the gap with Novo, which this week also lost a court bid to stop Lilly's ads. The guidance raise implies no supply or pricing brake yet. Retatrutide's head-to-head diabetes win adds a next leg, so the debate shifts from whether Lilly can grow to how much share it can take.
Industry NewsEli Lilly / Novo NordiskBioPharma Dive
Lilly's Retatrutide Tops Ozempic Head-to-Head in Type 2 Diabetes
- Lilly's Phase 3 TRANSCEND-T2D-2 pitted triple-agonist retatrutide against Ozempic 2 mg in roughly 1,300 adults with type 2 diabetes over 80 weeks, and hit its primary and key secondary endpoints.
- Both retatrutide doses cut A1C more than Ozempic and produced about twice the weight loss; the top dose carried more side effects and discontinuations.
- The trial was open-label and the data are company topline; Lilly plans regulatory filings in early 2027.
A head-to-head win over the diabetes market's reference product is the evidence payers and prescribers have been waiting for, and it lands on Novo's home turf rather than in obesity. The tolerability gap at the top dose is the caveat to watch: if dropouts hold up in full data, the 9 mg dose may be the commercial workhorse.
Industry NewsNovo Nordisk / Eli LillyBioPharma Dive
Judge Won't Pull Lilly's Obesity Ads as Novo Fails to Show Harm
- A federal judge refused Novo Nordisk's request for a preliminary injunction against Lilly's comparative Zepbound advertising.
- Novo failed to show harm: Wegovy prescriptions held steady during the April-July campaign, and the ads acknowledged a higher-dose Wegovy exists.
- Novo says the order does not decide whether the ads are false; its July false-advertising suit continues.
Flat Wegovy prescriptions through a months-long Lilly campaign is the quiet finding: it undercuts the idea that comparative messaging is moving share in obesity, and shows how hard injunctions are to win without measurable harm. The July suit still runs, but in a two-player GLP-1 market, expect the real contest to stay on data and access, not in court.
Industry NewsEli Lilly / METiS TechBioFierce Biotech
Lilly bets on Metis's AI platform for tissue-targeted lipid nanoparticles
- Eli Lilly and Hong Kong-listed METiS TechBio agreed a collaboration worth up to about $1.1 billion to develop tissue-specific delivery technologies.
- METiS contributes its AiLNP platform for ionizable lipid discovery, combining a large lipid library, screening and a lipid language model.
- Metis gets a low double-digit-million upfront, plus development, regulatory and commercial milestones and single-digit tiered royalties; no candidates or indications were named.
The headline figure is almost all contingent, so the real signal is the low-eight-figure upfront: Lilly is buying an option on delivery chemistry, not an asset. Extra-hepatic LNP targeting is the bottleneck for genetic medicines, and Lilly keeps stacking deals around it. For competitors in LNP design, the question is whether AI-generated lipid libraries can show reproducible tissue selectivity in vivo.
Industry NewsEli Lilly / Gate BioscienceFierce Biotech
Lilly roughly doubles its Gate Bioscience Sec61 pact, to up to $870M
- Lilly expanded its collaboration with Gate Bioscience to a potential value of up to $870M, from the original 2025 pact worth up to $856M.
- The expansion adds one target, with an option on a second; Gate gets an upfront payment, further payment if a second target is chosen, research funding and milestones.
- Gate's platform works on Sec61, the channel through which secreted and membrane proteins exit the cell; targets and indications are undisclosed.
An expansion rather than a new deal is the real signal: Lilly saw enough from the first target to pay for another. With Pfizer following into Sec61 with Enodia a week later, a small-molecule channel-modulation approach to 'undruggable' secreted proteins is turning into a crowded field. Undisclosed upfront and targets make the economics hard to judge.
Industry NewsEli LillySTAT News
FDA approves Lilly's Jaypirca for previously untreated CLL and SLL
- The FDA approved Jaypirca (pirtobrutinib) for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
- It moves the non-covalent BTK inhibitor from later-line use into the first-line setting.
First-line is where the BTK market's volume sits, so this is the label that matters commercially. It puts a non-covalent inhibitor directly against the covalent incumbents, where it competes on tolerability and on not depending on the Cys481 bond. Watch how payers and guidelines place it relative to fixed-duration venetoclax regimens.
Industry NewsEli LillySTAT News
Lilly's Amylin–Zepbound Combo Posts Record Weight Loss in Phase 2b, but Dropouts Rise
- EloraTZP combines the amylin agonist eloralintide with tirzepatide; in adults with obesity and type 2 diabetes it beat tirzepatide alone on weight loss and A1C at 48 weeks, with up to 23.3% weight loss at the top dose.
- Discontinuations due to adverse events were higher in the combination arms, mostly GI-related during dose escalation, which raises tolerability questions.
- Lilly plans to start phase 3 in the fourth quarter of 2026.
Beating retatrutide's diabetes-population number with an amylin add-on strengthens Lilly's case that obesity's next act is combinations, ahead of AbbVie and Pfizer amylin plays. The dropout rate is the real commercial variable: if titration cannot tame GI effects, a headline efficacy edge shrinks in practice. Phase 3 design, especially the dose-escalation schedule, will tell us how much of this is deliverable.
Industry NewsEli LillySTAT News
Lilly's Weekly Insulin Onswik Clears FDA
- The FDA approved Eli Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes, offering an alternative to daily long-acting injections.
- Approval drew on the QWINT trial program in over 3,400 patients, where Onswik's blood-sugar control was comparable to daily insulin glargine or degludec.
- Onswik is the second once-weekly basal insulin cleared in the US, after Novo Nordisk's Awiqli (icodec); Lilly expects US availability within months.
Second mover, not first: Onswik only claims non-inferiority to daily glargine/degludec in QWINT, so Lilly can't out-argue Awiqli on efficacy — it has to out-sell it, bundling weekly insulin into the same reps and formulary contracts as Trulicity/Mounjaro. Insulin, the industry's most commoditized category, just became the GLP-1 giants' next cross-sell battleground.
Industry NewsEli Lilly / InnoCare PharmaEndpoints News
Lilly Strikes Up to $3.35B Discovery Deal with China's InnoCare
- Eli Lilly signed a discovery-stage collaboration and licensing deal with Beijing-based InnoCare Pharma worth up to $3.35 billion.
- Terms include up to $100 million upfront, up to $3.25 billion in milestones, and royalties, as InnoCare hunts compounds against up to five undisclosed targets.
- It marks Lilly's fourth China-biotech deal since early 2025, after Insilico Medicine, Innovent Biologics and Haisco.
Fourth China-sourced discovery deal for Lilly since early 2025 — this is deliberate strategy, not opportunism: outsourcing early-target risk to lower-cost Chinese biotech engines. The $100M upfront against $3.35B total (~3%) is a cheap option on unproven targets, not a derisked buy. China's shifting from manufacturing base to discovery pipeline for Big Pharma.
Industry NewsKura Oncology / Caspian Therapeutics / Eli LillySTAT News
Kura Oncology Spins Off Caspian Therapeutics, Repurposing a Menin Inhibitor for Diabetes
- Kura Oncology spun off Caspian Therapeutics, a separately financed company pursuing menin inhibition for diabetes; Kura retains about 50% ownership, and CEO Troy Wilson chairs Caspian's board.
- Caspian launched with $50 million in financing led by BVF Partners, joined by Eli Lilly, T1D Fund, Invus, Montanova and Kura itself.
- Its lead candidate, KO-7246, targets the same menin-KMT2A interaction as Kura's FDA-approved leukemia drug ziftomenib, but is optimized for chronic metabolic disease rather than AML.
- Menin represses genes that limit pancreatic beta-cell growth; blocking it expanded beta-cell mass and boosted insulin production in preclinical type 1 and type 2 diabetes models.
- Caspian plans to file an IND and begin early trials assessing KO-7246's effects on beta-cell function and insulin output.
The spinout structure is the real story here: Kura offloads capital-intensive diabetes development onto a separately financed entity while keeping ~50% upside — a capital-efficient way to pursue a second indication without diluting the oncology balance sheet. Lilly's participation is the tell: not just funding, but a diabetes-franchise incumbent buying an option on a genuinely novel beta-cell-mass-expansion mechanism, distinct from GLP-1s and existing insulin-secretagogue classes. That novelty cuts both ways, though — menin inhibition is proliferative by design, and driving beta-cell expansion in pancreatic tissue carries an obvious tumorigenicity/hyperplasia overhang preclinical models won't fully resolve; watch how the IND-enabling tox package addresses it. Broader signal: oncology target biology migrating into metabolic disease is a repeatable playbook other biotechs with approved oncology assets may start mining.
Industry NewsEli Lilly / Merida BiosciencesFierce Biotech
Lilly to Acquire Merida Biosciences in Up to $2.88B Autoimmune Deal
- Eli Lilly will acquire privately held Merida Biosciences for up to $2.88 billion, combining upfront and milestone payments; the deal is expected to close in Q4 2026.
- Merida engineers biologics that selectively degrade disease-causing autoantibodies, aiming to target the root biology of autoimmune and allergic disease rather than broadly suppress immunity.
- Lead candidate MER511 is in early-stage testing for Graves' disease and thyroid eye disease, with initial data pointing to reductions in thyroid-stimulating autoantibodies.
- The pipeline also includes MER769, a preclinical antibody targeting underlying allergy biology, with potential relevance to food allergy, asthma, and chronic urticaria.
- The deal is Lilly's 13th acquisition of 2026, extending an obesity/diabetes-funded buying spree into new autoimmune and allergy modalities.
Autoantibody degradation goes after a gap FcRn inhibitors like Vyvgart can't close — those broadly dial down IgG, this targets the specific rogue antibodies. If MER511's Graves' data hold, it's a cleaner mechanism story than another B-cell depleter. The structure says Lilly isn't paying for hope: milestone-heavy pricing on preclinical/Phase 1 assets pushes the risk onto Merida's team hitting data, not onto Lilly's balance sheet. $2.88B is reasonable for a validated new modality, rich if MER511 stalls. It slots next to lebrikizumab and mirikizumab without cannibalizing either. The real signal is deal #13 this year — Lilly's recycling GLP-1 cash into next-gen immunology and allergy bets while it still has the war chest to shop early.